Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry-Reference-Cited by-同舟云学术

Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

Published:2022-12-01 Issue:6 Volume:187 Page:1022-1024
ISSN:1365-2133
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Stölzl Dora¹^ORCID,Sander Nicole¹,Heratizadeh Annice²^ORCID,Haufe Eva³,Harder Inken¹,Abraham Susanne⁴^ORCID,Heinrich Luise³,Kleinheinz Andreas⁵,Wollenberg Andreas⁶,Weisshaar Elke⁷,Schäkel Knut⁸^ORCID,Ertner Konstantin⁹,Wiemers Franca¹⁰,Wildberger Julia¹¹,Worm Margitta¹²^ORCID,von Kiedrowski Ralph¹³,Effendy Isaak¹⁴,Asmussen Andrea¹⁵,Augustin Matthias¹⁶^ORCID,Pawlak Mario¹⁷,Sticherling Michael¹⁸^ORCID,Zink Alexander¹⁹^ORCID,Hilgers Melanie²⁰,Handrick Christiane²¹,Quist Sven²²,Schwarz Beate²³,Staubach-Renz Petra²⁴,Bell Magnus²⁵,Hong-Weldemann Sun-Hei²⁶,Homey Bernhard²⁷,Brücher Jens-Joachim²⁸,Schmitt Jochen³,Werfel Thomas²,Weidinger Stephan¹^ORCID,

Affiliation:

1. Center for Inflammatory Skin Diseases, Department of Dermatology and Allergy University Hospital Schleswig-Holstein Campus Kiel Kiel Germany

2. Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy Hannover Medical School Hannover Germany

3. Center of Evidence-based Healthcare University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden Dresden Germany

4. Department of Dermatology University Allergy Center, Medical Faculty Carl Gustav Carus, TU Dresden Germany

5. Clinics for Dermatology Elbe Klinikum Buxtehude Germany

6. Clinics and Outpatient Clinics for Dermatology and Allergy LMU Munich Germany

7. Occupational Dermatology, Department of Dermatology Ruprecht-Karls University Heidelberg Germany

8. Department of Dermatology Ruprecht-Karls University Heidelberg Germany

9. Practice Dr. med. Konstantin Ertner Nürnberg Germany

10. Practice Dr. med. Franca Wiemers Leipzig Germany

11. Practice Dr. med. Julia Wildberger, Hautmedizin, Bad Soden Germany

12. Clinics for Dermatology Venerology and Allergy Charité Berlin Germany

13. CMSS – Company for Medical Study and Service Selters Westerwald Germany

14. Department of Dermatology Hospital Rosenhoehe Bielefeld Germany

15. Practice Dr. med. Andrea Asmussen Dermatology at Lesum Bremen Germany

16. Institute for Health Services Research in Dermatology Hamburg University Medical Center Hamburg-Eppendorf Germany

17. Practice Dr. med. Anika Hünermund and Mario Pawlak Heilbad Heiligenstadt Germany

18. Department of Dermatology University Hospital, Friedrich-Alexander-University Erlangen-Nuernberg Germany

19. Department of Dermatology and Allergy, School of Medicine Technical University of Munich and Clinical Unit Allergology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH Germany

20. Clinics for Dermatology and Allergy University Hospital Aachen Germany

21. Practice Dr. med. Christiane Handrick Berlin Germany

22. Dermatology Clinic Helix Medical Excellence Center Mainz Germany

23. Practice Dr. med. Beate Schwarz Langenau Germany

24. Department of Dermatology and Allergy University Medical Center Mainz Germany

25. Practice Dr. med. Magnus Bell Thomas Kaiser Andernach Germany

26. Practice Dr. med. Sun-Hei Hong-Weldemann Freiburg Germany

27. Department of Dermatology Heinrich-Heine-University Duesseldorf Germany

28. Hautambulatorium Magdeburg Germany

Abstract

Abstract This interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.21794

Reference7 articles.

1. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis;Simpson;N Engl J Med,2016

2. Biologics for treatment of atopic dermatitis: current status and future prospect;Ratchataswan;J Allergy Clin Immunol Pract,2021

3. A new era has begun: treatment of atopic dermatitis with biologics;Stölzl;Allergol Select,2021

4. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis;Drucker;JAMA Dermatol,2022

5. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: first results of the German Atopic Eczema Registry TREATgermany;Schmitt;J Dtsch Dermatol Ges,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: single-center, retrospective study;Scientific Reports;2024-07-23

2. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China;Archives of Dermatological Research;2024-05-31

3. Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics;International Journal of Molecular Sciences;2024-05-09

4. Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry;Allergy;2024-05-07

5. Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab;Journal of the European Academy of Dermatology and Venereology;2024-04-30